The Pathophysiological Significance of Dual Inhibition of IL-17A and IL-17F in Psoriatic Arthritis and Axial Spondyloarthritis.

Taltz (ixekizumab) - Eli Lilly

Bimzelx (bimekizumab-bkzx) - UCB

Cosentyx (secukinumab) - Novartis

izokibep (ABY-035) - Affibody

sonelokimab (M1095) - Avillion, MoonLake Immunotherap

http://www.ncbi.nlm.nih.gov/pubmed/41648061

Andreas V Goules; Olga Katsouli; Panayiotis G Vlachoyiannopoulos; Vasileios Lainis

Feb 6, 2026